Faron Pharmaceuticals Oy (FARN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Faron Pharmaceuticals Oy (FARN) has a cash flow conversion efficiency ratio of 0.000x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (GBX-5.21K ≈ $-0.63 USD) by net assets (GBX-16.25 Million ≈ $-1.98K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Faron Pharmaceuticals Oy - Cash Flow Conversion Efficiency Trend (2012–2024)
This chart illustrates how Faron Pharmaceuticals Oy's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read debt load of Faron Pharmaceuticals Oy for a breakdown of total debt and financial obligations.
Faron Pharmaceuticals Oy Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Faron Pharmaceuticals Oy ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Chariot Oil & Gas Limited
LSE:CHAR
|
-0.127x |
|
NEWPATH RESOURCES INC.
F:0MZ
|
N/A |
|
PROMIS NEUROSCIENCES
F:23J0
|
N/A |
|
Reliance Industries Limited
IL:RIGD
|
N/A |
|
ORUM
KQ:475830
|
-0.045x |
|
ArcelorMittal SA
LSE:0RP9
|
0.077x |
|
MEDICOX Co. Ltd
KQ:054180
|
-0.040x |
|
STV Group plc
LSE:STVG
|
-0.602x |
Annual Cash Flow Conversion Efficiency for Faron Pharmaceuticals Oy (2012–2024)
The table below shows the annual cash flow conversion efficiency of Faron Pharmaceuticals Oy from 2012 to 2024. For the full company profile with market capitalisation and key ratios, see FARN stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | GBX-9.76 Million ≈ $-1.19K |
GBX-22.97 Million ≈ $-2.79K |
2.353x | +49.86% |
| 2023-12-31 | GBX-15.16 Million ≈ $-1.84K |
GBX-23.81 Million ≈ $-2.90K |
1.570x | -21.63% |
| 2022-12-31 | GBX-11.48 Million ≈ $-1.40K |
GBX-22.99 Million ≈ $-2.80K |
2.004x | +126.31% |
| 2021-12-31 | GBX2.92 Million ≈ $355.04 |
GBX-22.22 Million ≈ $-2.70K |
-7.614x | -180.55% |
| 2020-12-31 | GBX-1.85 Million ≈ $-224.97 |
GBX-17.48 Million ≈ $-2.13K |
9.453x | +232.08% |
| 2019-12-31 | GBX1.61 Million ≈ $195.89 |
GBX-11.52 Million ≈ $-1.40K |
-7.157x | -12767.17% |
| 2018-12-31 | GBX369.00K ≈ $44.90 |
GBX-20.52K ≈ $-2.50 |
-0.056x | +98.56% |
| 2017-12-31 | GBX4.74 Million ≈ $577.09 |
GBX-18.36 Million ≈ $-2.23K |
-3.872x | -398.52% |
| 2016-12-31 | GBX10.88 Million ≈ $1.32K |
GBX-8.45 Million ≈ $-1.03K |
-0.777x | -21.48% |
| 2015-12-31 | GBX11.18 Million ≈ $1.36K |
GBX-7.15 Million ≈ $-869.46 |
-0.639x | -295.24% |
| 2014-12-31 | GBX-1.19 Million ≈ $-144.55 |
GBX-389.00K ≈ $-47.33 |
0.327x | -59.54% |
| 2013-12-31 | GBX-949.00K ≈ $-115.47 |
GBX-768.00K ≈ $-93.44 |
0.809x | -70.13% |
| 2012-12-31 | GBX-837.00K ≈ $-101.84 |
GBX-2.27 Million ≈ $-275.95 |
2.710x | -- |
About Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy operates as a clinical stage drug discovery and development company. Its lead product candidates are Traumakine, an investigational intravenous interferon beta-1a therapy for the prevention from cytokine release syndrome (CRS), or ischemia and hyperinflammatory conditions; and Bexmarilimab, a novel anti-Clever-1 humanized antibody that targets a subpopulation of tumor-ass… Read more